Intravitreal bevacizumab (avastin) as an adjuvant treatment in cases of neovascular glaucoma
Open Access
- 1 January 2009
- journal article
- research article
- Published by Medknow in Middle East African Journal of Ophthalmology
- Vol. 16 (2) , 75-9
Abstract
Purpose: To evaluate the effect of intravitreal bevacizumab (avastin) injection in cases of neovascular glaucoma. Study Design: Clinical case series. Materials and Methods: Sixteen eyes of 16 patients with rubeosis iridis and secondary glaucoma were administered intravitreal injection of bevacizumab (2.5 mg). The patients were followed for 2 months. Results: We noted partial or complete regression of iris neovascularization 1 week after injection of bevacizumab. Reproliferation of new vessels was detected in 25% of the cases after 2 months. The mean intraocular pressure (IOP) before injection was 28? 9.3 mm Hg under topical β-blocker and systemic acetazolamide. One week after injection, the IOP decreased to 21.7? 11.5 mm Hg (5 cases without anti-glaucoma drugs, 6 cases with topical β-blocker and 5 cases with both topical β-blocker and systemic acetazolamide). Conclusion: Intravitreal bevacizumab (avastin) injection leads to regression of iris neovascularization with subsequent drop of IOP in eyes with neovascular glaucoma.Keywords
This publication has 12 references indexed in Scilit:
- Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular GlaucomaAmerican Journal of Ophthalmology, 2006
- Regression of Iris Neovascularization After Intravitreal Injection of Bevacizumab in Patients With Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 2006
- Short‐term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucomaActa Ophthalmologica Scandinavica, 2006
- RAPID IMPROVEMENT OF RUBEOSIS IRIDIS FROM A SINGLE BEVACIZUMAB (AVASTIN) INJECTIONRetina, 2006
- Intravitreal Bevacizumab in a Patient With Neovascular GlaucomaOphthalmic Surgery, Lasers and Imaging Retina, 2006
- REGRESSION OF RETINAL AND IRIS NEOVASCULARIZATION AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENTRetina, 2006
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman PrimateArchives of Ophthalmology (1950), 1996
- Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.1994
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989